Copley Acquisition Corp 8-K

What Happened
Copley Acquisition Corp (the SPAC) announced it entered a Business Combination Agreement with Ignite Proteomics, LLC on June 10, 2026 to combine the companies into a newly public operating company (Pubco). The deal contemplates Copley re-domiciling from the Cayman Islands to Delaware, two mergers (SPAC Merger and Company Merger) effectuating the exchange of Copley shares and Ignite membership interests for Pubco common stock, and conversion of existing SPAC warrants into Pubco warrants. The aggregate Merger Consideration payable to Ignite’s sellers is $150,000,000 (treated as $150,000,000 / $10 = 15,000,000 shares of Pubco Common Stock). A sponsor-related cash payment of $4,000,000 will be paid at closing to Copley Acquisition Sponsors Limited. The parties filed a press release on June 11, 2026 and included related agreements (seller support, insider letter amendment, guaranty).

Key Details

• Merger Consideration: $150,000,000 total, equivalent to 15,000,000 Pubco shares at $10.00 per share.
• Sponsor payment: $4,000,000 in cash to Copley Acquisition Sponsors Limited at closing.
• Minimum cash conditions: SPAC Minimum = $15,000,000 (trust + Copley financings); Company Minimum = $7,500,000 (Ignite financings). Copley aims to raise up to $20M of Transaction Financing; Ignite up to $10M.
• Closing timeline and approvals: Agreement signed June 10, 2026; closing subject to shareholder/member approvals, regulatory clearances, effectiveness of an S-4 registration statement, NYSE listing, and other customary conditions; outside termination date Sept 30, 2026 (unless extended).
• Other agreements: Seller Support Agreements (holders committed to vote in favor), Insider Letter Amendment (lock-up terms; founder lock-up expires on earlier of 90 days after closing or certain liquidity events), a Guaranty from Aditxt Inc., and expected 90‑day lock-ups for sellers and certain directors/officers. Pubco to adopt an equity incentive plan equal to 15% of post-closing shares; Pubco board to be seven directors designated by Ignite with at least four NYSE-independent directors.

Why It Matters
This filing formalizes a SPAC business combination that would make Ignite Proteomics the operating business of a newly public company (Pubco) and convert current Copley public holders into Pubco shareholders (or allow redemptions per the S-4 process). Key investor considerations from the filing: (1) the deal requires minimum post-redemption cash thresholds ($15M and $7.5M as noted) and other customary closing conditions, so financing and shareholder approvals are material to completion; (2) Ignite waived any claim to Copley’s trust account funds; (3) representations in the agreement generally do not survive closing and there are limited indemnity rights, which affects remedies if problems arise after closing; and (4) a named parent (Aditxt Inc.) has guaranteed Ignite’s obligations. Retail investors should watch the S-4/proxy filing, the redemption window, and any updates on the financing and regulatory approvals.